The expression of IL-7RA in Egyptian patients with multiple sclerosis

被引：0
作者：
Elshafie S. [1 ]
Abdel Rasol H.A. [1 ,2 ]
Helmy H. [3 ]
Younan S. [4 ]
机构：
[1] Clinical and Chemical Pathology Department, Fayoum University, Fayoum
[2] Taibah University, Al Madinah Al Munawara
[3] Neurology Department, Cairo University, Giza
[4] Clinical and Chemical Pathology Department, Ministry of Health, Fayoum
来源：
Comparative Clinical Pathology | 2015年 / 24卷 / 5期
关键词：
IL-7R; Multiple sclerosis;
D O I：
10.1007/s00580-015-2064-5
中图分类号：
学科分类号：
摘要：
Multiple sclerosis has a clinically significant heritable component. The interleukin 7 receptor alpha (IL-7RA) has been recognized as a susceptibility gene for multiple sclerosis (MS). It is known that demographic, environmental factors, as well as population genetic background have a substantial role in multiple sclerosis development. The aim of the present study was to assess the relevance of IL-7RA messenger RNA (mRNA) gene expression level in peripheral blood mononuclear cells (PBMC) on MS phenotype (including clinical and magnetic resonance imaging (MRI) parameters). A total of 31 unrelated Egyptian patients with MS compared to 14 unrelated matched healthy controls were included in the study. IL-7RA VEGF-A gene expression and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a housekeeping gene were measured by real-time polymerase chain reaction (RT-PCR) using SYBR Green technique. IL-7RA mRNA gene expression level was significantly lower in the MS group compared to the control group (p < 0.001). Reduced mRNA IL-7RA expression was observed both in patients with MS compared to the control group and in stratified analysis of MS subtypes: primary progressive MS (PPMS), relapsing progressive MS (RPMS), and secondary progressive MS (SPMS). IL-7RA mRNA gene expression level was not significantly different in MS patients in relapse compared to those in remission (p > 0.05). There was no statistically significant difference in IL-7RA mRNA gene expression level among MS patients with MRI ≥9 brain lesions compared to MS subjects with MRI <9 brain lesions (p > 0.05). IL-7RA mRNA gene expression level cannot be used as a stratifying tool in determining disease course. There was no correlation between IL-7RA mRNA gene expression levels and neither age, age of onset, duration of disease, multiple sclerosis progression index, nor expanded disability status scale. These results confirm the involvement of mRNA gene expression of IL-7RA in MS pathogenesis and suggest that IL-7RA variation may primarily affect chronic disease course. © 2015, Springer-Verlag London.
引用
收藏
页码：1223 / 1230
页数：7
相关论文
共 56 条
[1]  
Akkad D.A., Hoffjan S., Petrasch-Parwez E., Beygo J., Gold R., Epplen J.T., Variation in the IL7RA and IL2RA genes in German multiple sclerosis patients, J Autoimmun, 32, pp. 110-115, (2009)
[2]  
Alcina A., Fedetz M., Ndagire D., Fernandez O., Leyva L., Guerrero M., Et al., The T244I variant of the interleukin-7 receptor-alpha gene and multiple sclerosis, Tissue Antigens, 2, pp. 158-161, (2008)
[3]  
Aulchenko Y.S., Hoppenbrouwers I.A., Ramagopalan S.V., Broer L., Jafari N., Hillert J., Et al., Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis, Nat Genet, 40, pp. 1402-1403, (2008)
[4]  
Baecher-Allan C., Hafler D.A., Human regulatory T cells and their role in autoimmune disease, Immunol Rev, 212, pp. 203-216, (2006)
[5]  
Baranzini S.E., Wang J., Gibson R.A., Galwey N., Naegelin Y., Barkhof F., Et al., Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis, Hum Mol Genet, 18, pp. 767-778, (2009)
[6]  
Bielekova B., Muraro P.A., Golestaneh L., Pascal J., McFarland H.F., Martin R., Preferential expansion of autoreactive T lymphocytes from the memory T-cell pool by IL-7, J Neuroimmunol, 100, pp. 115-123, (1999)
[7]  
Burchill M.A., Yang J., Vang K.B., Farrar M.A., Interleukin-2 receptor signaling in regulatory T cell development and homeostasis, Immunol Lett, (2007)
[8]  
Concannon P., Rich S.S., Nepom G.T., Genetics of type 1A diabetes, N Engl J Med, 360, pp. 1646-1654, (2009)
[9]  
Dawson B., Trapp R.G., Basic and clinical biostatistics, 3rd ed, Mcgraw-Hill Inc, (2001)
[10]  
De Jager P.L., Hafler D.A., New therapeutic approaches for multiple sclerosis, Annu Rev Med, pp. 417-432, (2007)
123456